Grievink, Hendrika W <br/><br/>
DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers.  [electronic resource] 

 -  Clinical pharmacology and therapeutics  02 2020 
 - 406-414 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-6535 
<br/><br/><label>Standard No.: </label>10.1002/cpt.1615  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Area Under Curve<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Half-Life<br/>Humans<br/>Leukocytes, Mononuclear--drug effects<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Phosphorylation--drug effects<br/>Receptor-Interacting Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Young Adult